Fennec Announces Results of Annual Meeting
Fennec Pharmaceuticals announced the results of its Annual General and Special Meeting of Shareholders held on June 10, 2025. All five director nominees were elected, receiving between 93.6% and 97.8% of votes cast. Shareholders also approved the appointment of Haskell & White LLP as auditors (99.6%) and the executive compensation report (85.5%). An amendment to the 2020 Equity Incentive Plan was approved by 91.3% of votes (88.0% excluding insider shares).
Key figures
- Auditor approval pct
- 99.64
- Exec comp approval pct
- 85.5
- Equity plan amendment approval pct
- 91.27
- Equity plan amendment approval excl insiders pct
- 88.01
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.